Clinical trials: Hydroxychloroquine
Covid19, Progression
Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression
Brief Summary: Purpose of this study is to evaluate efficacy of hydroxychloroquine (HCQ) in reducing progression of Corona Virus Disease 2019 (COVID - 19) and achieving viral clearance.
- Trial name
- COVID-19 (NCT04491994)
- Testing
- HCQ
- Where
- Pakistan
- Volunteers
- 540 people
- Sponsor
- UNICEF
Type1 Diabetes Mellitus
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.
- Trial name
- TN-22 (NCT03428945)
- Testing
- Hydroxychloroquine
- Where
- 51 sites in United States, Australia and 4 more
- Volunteers
- 273 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
COVID-19
The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)
The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts.
- Trial name
- PATCH (NCT04329923)
- Testing
- Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day
- Where
- United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Ravi Amaravadi, MD
Rheumatoid Arthritis
Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects
To assess comparative radiographic efficacy, clinical efficacy and safety of etanercept (ETN) + methotrexate (MTX) with usual disease-modifying anti-rheumatic drug (DMARD) treatment in subjects with moderate RA who were treated…
- Trial name
- NCT00706797
- Testing
- etanercept (EnbrelTM), methotrexate
- Where
- 45 sites in Czechia, France and 7 more
- Volunteers
- 141 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hidradenitis Suppurativa, Hidradenitis
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is an under-recognized and debilitating disease. Patients suffer from recurring painful abscesses and scarring in their armpits, under the breasts, groin and other areas of the body.
- Conditions
- Hidradenitis Suppurativa, Hidradenitis, Acne Inversa, Boils
- Trial name
- NCT03275870
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Elena Gonzalez Brant, MD
Porphyria Cutanea Tarda
Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
Porphyria cutanea tarda (PCT) is an iron-related disorder that responds to treatment by phlebotomy or low-dose hydroxychloroquine, but comparative data on these treatments are limited.
- Trial name
- NCT01573754
- Testing
- Hydroxychloroquine, Phlebotomy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Systemic Lupus Erythematosus (SLE), Juvenile SLE
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness.
- Conditions
- Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus
- Trial name
- NCT03122431
- Testing
- Thalidomide, Hydroxychloroquine reduced, standard dose of HCQ
- Where
- Brazil
- Volunteers
- 93 people
- Sponsor
- University of Sao Paulo General Hospital
B-Cell Chronic Lymphocytic Leukemia
Hydroxychloroquine in Untreated B-CLL Patients
Eligible CLL patients who sign an informed consent will be started on hydroxychloroquine 400mg po daily for up to one year. They will be monitored for disease status as well as adverse reactions after two weeks and then every 4…
- Trial name
- NCT00771056
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Northwell Health
Rheumatoid Arthritis
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment…
- Trial name
- TEAR (NCT00259610)
- Testing
- methotrexate, sulfasalazine, hydroxychloroquine
- Where
- United States
- Volunteers
- 755 people
- Sponsor
- University of Alabama at Birmingham
COVID-19
Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients
This research is designed as an open-label,non-comparative prospective trial.
- Trial name
- NCT04458948
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of New Mexico
SARS-CoV Infection, Covid19
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a combination of three medications currently used to treat other viral infections could be effective in fighting this new virus.
- Trial name
- TriACT (NCT04605588)
- Testing
- Nitazoxanide, Ribavirin, Hydroxychloroquine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rutgers, The State University of New Jersey
Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Efficacy and Safety of Itolizumab in COVID-19 Complications
Randomized, Parallel Group, Active Controlled Trial
- Conditions
- Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19
- Trial name
- NCT04475588
- Testing
- Itolizumab IV infusion, Best supportive care (BSC)
- Where
- 4 sites in India
- Volunteers
- 32 people
- Sponsor
- Biocon Limited
Lupus Erythematosus, Systemic
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
The purpose of this study is: 1. To assess the efficacy of a lipid-lowering agent (atorvastatin) on the development of atherosclerosis that predisposes children with SLE to cardiovascular events in adulthood. 2.
- Trial name
- NCT00065806
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Laura Schanberg
Rheumatoid Arthritis
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
This Phase IIIb, multicenter, open label, single arm study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab as monotherapy or in combination with methotrexate or other non-biologic DMARDs in participants…
- Trial name
- NCT01941095
- Testing
- Azathioprine, Chloroquine, Hydroxychloroquine
- Where
- 10 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Bile Duct Cancer, Biliary Cancer
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Background: Bile duct cancer is cancer of the slender tubes of the biliary tract. These tubes carry bile through the liver. Such cancer tumors often have an abnormal or mutated gene.
- Conditions
- Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
- Trial name
- NCT04566133
- Testing
- Trametinib, Hydroxychloroquine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Systemic Lupus Erythematosus
Study of Anti-Malarials in Incomplete Lupus Erythematosus
This project is a multicenter, randomized, placebo-controlled, double-blind clinical trial that is designed to test whether treating patients who are at risk for development of lupus with hydroxychloroquine can slow accumulation…
- Trial name
- SMILE (NCT03030118)
- Testing
- Hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 187 people
- Sponsor
- Milton S. Hershey Medical Center
Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
The purpose of this study is to examine the combination of one standard treatment for lung cancer plus an additional drug, hydroxychloroquine.
- Conditions
- Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01649947
- Testing
- Paclitaxel, Carboplatin, Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Rutgers, The State University of New Jersey
Rheumatoid Arthritis
Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region
The purpose of this study is to compare the efficacy of etanercept with usual disease-modifying anti-rheumatic drug (DMARD) therapy in the treatment of moderate to severe rheumatoid arthritis (RA) over 16 weeks in the Asia…
- Trial name
- NCT00422227
- Testing
- Etanercept , Methotrexate, Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide
- Where
- 27 sites in Hong Kong, India and 6 more
- Volunteers
- 300 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
COVID-19
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with…
- Trial name
- NCT04333225
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
RA
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
Primary Objective: To collect real-use data of the sarilumab auto-injector device (AID) used by rheumatoid arthritis (RA) participants.
- Trial name
- SARIL-RA-EASY (NCT02057250)
- Testing
- Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS)
- Where
- 53 sites in United States, Chile and 4 more
- Volunteers
- 217 people
- Sponsor
- Sanofi